Tecentriq combined with BCG did not enhance outcomes for high-risk NMIBC patients compared to BCG alone, with similar event-free survival rates. The ALBAN trial reported higher rates of side effects ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Complete response reported in 75 percent of patients with BCG-unresponsive, non-muscle-invasive bladder cancer.

A Mayo Clinic-led international phase 3 study found that a new immunotherapy helped many patients with an aggressive form of bladder cancer keep their bladder instead of having it surgically removed.

What Is Imfinzi, and Why Does It Matter? Imfinzi (durvalumab) is a prescription immunotherapy medicine used to treat different types of cancer. The FDA has approved the combination of Imfinzi and ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...

Adding durvalumab to Bacillus Calmette-Guérin (BCG) induction (I) and maintenance (M) does not meaningfully improve patient-reported outcomes (PROs) at 5 years among patients with non-muscle invasive ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Share on Pinterest A new urine test may enable more personalized treatment for bladder cancer. Image credit: SolStock/Getty Images A new urine-based test can detect minimal residual bladder cancer ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the ...